Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend the claims as follows:

Claims 1 - 5. (Cancelled)

6. (Currently amended) A cell suspension according to claim [5] 29 prepared from autologous cells.

Claims 7 - 13. (Cancelled)

14. (Currently amended) A cell suspension according to claim [5] 29 wherein the physical and or chemical dissociating means comprises a chemical dissociating means comprising an enzyme solution.

15. (Previously presented) A cell suspension according to claim 14 wherein the enzyme solution comprises an enzyme selected from the group consisting of trypsin, trypsin-EDTA, dispase, collagenase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain.

16. (Previously presented) A cell suspension according to claim 15 wherein the enzyme solution comprises between about 5% and about 0.1% trypsin per volume of solution.

17. (Previously presented) A cell suspension according to claim 16 wherein the enzyme solution comprises between about 2.5% and about 0.25% trypsin per volume of solution.

18. (Previously presented) A cell suspension according to claim 14 wherein the enzyme solution is heated.

19. (Previously presented) A cell suspension according to claim 18 wherein the enzyme solution is heated to a temperature between about 30 degrees Celsius and about 37 degrees Celsius.

20. (Previously presented) A cell suspension according to claim 14 wherein the enzyme solution is calcium and magnesium free.

21. (Previously presented) A cell suspension according to claim 20 wherein the enzyme solution is provided in a calcium and magnesium ion free phosphate buffered saline.

22. (Currently amended) A cell suspension according to claim [5] 29 wherein the tissue sample comprises a tissue biopsy derived from skin.

23. (Currently amended) A cell suspension according to claim [5] 29 wherein the nutrient solution comprises a salt solution.

24. (Currently amended) A cell suspension according to claim [5] 29 wherein the nutrient solution comprises physiological saline.

25. (Currently amended) A cell suspension according to claim [5] 29 wherein the filtering step comprises the use of a filter size between about 50μm and about 200μm.

26. (Previously presented) A cell suspension according to claim 25 wherein the filtering step comprises the use of a filter size between about 75μm and about 150μm.

Claims 27 - 28. (Cancelled)

29. (New) A cell suspension produced according to a method comprising the steps of:

(a) physically and/or chemically dissociating cellular stratum in a tissue sample, to provide cells suitable for grafting to a patient;

(b) harvesting the cells in the presence of a nutrient solution; and

(c) filtering the cells in nutrient solution to remove cell conglomerates,

wherein the resulting cell suspension is free of xenogenic serum and cell conglomerates, the cells remain viable, and the suspension is suitable for direct application to a region on a patient undergoing tissue grafting.

30. (New) A cell suspension according to claim 29, wherein the suspension is produced according to a method comprising the steps of:

(a) subjecting a tissue sample including cells suitable for grafting to a patient, to a heated enzyme solution capable of dissociating cellular stratum in the tissue

sample, the heated enzyme solution being calcium and magnesium free and comprising an enzyme selected from the group consisting of trypsin, trypsin-EDTA, dispase, collagenase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain;

(b) removing the tissue sample from the dissociating means used in step (a) and harvesting in the presence of a nutrient solution cells from the tissue sample, cells suitable for grafting on to a patient wherein the nutrient solution comprises physiological saline and is (i) free of xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient and (iii) is suitable for direct application to a region on a patient undergoing tissue grafting; and

(c) filtering the cellular suspension produced according to step (b) with a filter size between about 50μm and about 200μm to remove large cellular conglomerates.

31. (New) A cell suspension according to claim 29, the suspension being produced according a method comprising the steps of:

(a) subjecting a tissue sample including cells suitable for grafting to a patient, to a heated enzyme solution capable of dissociating cellular stratum in the tissue sample, the heated enzyme solution comprising a calcium and magnesium ion free phosphate buffered saline and between about between about 5% and about 0.1% trypsin per volume of solution, the heated enzyme solution being heated to a temperature between about 30 degrees Celsius and about 37 degrees Celsius;

(b) removing the tissue sample from the dissociating means used in step (a) and harvesting in the presence of a nutrient solution cells from the tissue sample, cells suitable for grafting on to a patient wherein the nutrient solution comprises physiological saline and is (i) free of xenogenic serum, (ii) capable of maintaining the viability of the cells until applied to a patient and (iii) is suitable for direct application to a region on a patient undergoing tissue grafting; and

(c) filtering the cellular suspension produced according to step (b) with a filter size between about 75μm and about 150μm to remove large cellular conglomerates.